Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 15 2022 - 6:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. .
.
. Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
BLOCK LISTING SIX MONTHLY RETURN
Date: 15
November 2022
|
Name of applicant:
|
GSK plc
|
|
Name of scheme:
|
GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan
|
|
Period of return:
|
From:
|
1 May 2022
|
To:
|
31 October 2022
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
44,219
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
0
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
44,219
|
|
Name of applicant:
|
GSK plc
|
|
Name of scheme:
|
GlaxoSmithKline plc Share Save Plan 2012
|
|
Period of return:
|
From:
|
1 May 2022
|
To:
|
31 October 2022
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
1,373,495
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
251,620
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
1,121,875
|
|
Name of contact:
|
Victoria Whyte
|
|
Telephone number of contact:
|
020 8047 5000
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
15, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
